Multi‑Mode Cognitive Processing Therapy for adults with PTSD
Official title: Efficacy of Multi-Modal Cognitive Processing Therapy for PTSD: A Longitudinal, Multicenter, Single-Blind RCT on Symptoms, Sleep, Anxiety, Depression, Remission, and Posttraumatic Growth
Run by Far Eastern Memorial Hospital · NCT07105345 · Data updated 2026-11-12
This program will try a multi‑mode form of Cognitive Processing Therapy to reduce PTSD symptoms and improve sleep and mood in adults aged 20–65 with PTSD.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 20 Years to 65 Years |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Far Eastern Memorial Hospital Academic / other |
| Locations | 1 site (New Taipei City, Banqiao District) |
| Status | Recruiting |
| Started | September 1, 2025 |
| Main results expected | June 30, 2027 |
| Study ends | December 31, 2027 |
| Registry record updated | September 3, 2026 |
| Trial ID | NCT07105345 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 20–65 with a DSM‑5 diagnosis of PTSD, a PCL‑5 score of 33 or higher, ability to consent, and a stable psychiatric medication regimen (if any) for at least 4 weeks are the intended participants.
✕Probably not a fit
People with psychotic disorders, bipolar I, current substance dependence, recent severe suicidal behavior, significant cognitive or neurological impairment, or those already in other psychological PTSD treatments are unlikely to benefit from participating.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a single‑blind, randomized, two‑arm longitudinal trial comparing Multi‑Mode Cognitive Processing Therapy (MMCPT) to treatment‑as‑usual (TAU) for patients with DSM‑5 PTSD. MMCPT follows the Resick CPT manual delivered as twelve weekly 90‑minute individual sessions by trained therapists, with rigorous monitoring of treatment fidelity and safety. Primary outcomes are clinician‑rated and self‑report PTSD severity (CAPS‑5 and PCL‑5); secondary outcomes include sleep measures (actigraphy, PSQI), anxiety (STAI), depression (HDRS‑17), remission rates, and posttraumatic growth (PTGI). Participants are assessed at baseline, mid‑treatment, post‑treatment, and at 3, 6, 9, and 12 months to capture short‑ and longer‑term effects.
Why it matters
Potential benefit: If successful, MMCPT could reduce PTSD symptoms and improve sleep, anxiety, depression, and long‑term recovery for adults with PTSD.
How similar studies have gone: Cognitive Processing Therapy is an evidence‑based treatment with many RCTs showing symptom reduction in PTSD, though this specific multi‑mode adaptation and its focused effects on sleep and long‑term outcomes are less established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged between 20 and 65 years * Diagnosed with PTSD according to DSM-5 criteria * Score ≥ 33 on the PTSD Checklist for DSM-5 (PCL-5) * Able to provide informed consent * Stable psychiatric medication regimen (if any) for at least 4 weeks prior to enrollment Exclusion Criteria: * Diagnosed with schizophrenia, schizoaffective disorder, or bipolar I disorder * Current substance dependence or abuse within the past 6 months * Severe suicidal ideation or suicide attempt in the past 6 months * Cognitive impairment or neurological disorder affecting participation * Concurrent participation in other psychological treatment for PTSD
Where it's running
-
Far Eastern Memorial Hospital
New Taipei City, Banqiao District, Taiwan Recruiting
Study contacts
- Study coordinator: Hsin-I Liu, PhD, RN
- Email: femh91095@femh.org.tw
- Phone: +886-2-8966-7000
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Reboxetine plus Ritalin vs Dog-Assisted Therapy for PTSD
This study tests whether a drug combo of reboxetine and methylphenidate works better than dog-assisted therapy for people with PTSD.
-
Self-Help CPT with WoVeN Peer Support for Women Veterans with PTSD
This study tests a self-help Cognitive Processing Therapy and a WoVeN peer-support program, alone and together, to see if they improve PTSD symptoms and well-being for women veterans.
-
Adaptive, personalized PTSD care for veterans
This program will try different therapy sequences plus optional text-message homework reminders to see if switching treatments or sending prompts helps veterans with PTSD who aren't improving or are missing between-session homework.
-
Improving thinking, daily functioning, mood, and sleep after mild traumatic brain injury and PTSD
This project will test whether adding morning bright light therapy to compensatory cognitive training helps post-9/11 Veterans with mild traumatic brain injury and PTSD think, function, and sleep better compared with a neutral ion generator.
-
Combined MDMA and psilocybin treatment for Veterans with PTSD
This trial tests whether giving MDMA followed 30 minutes later by psilocybin can be safely used to reduce symptoms in military veterans with long-standing PTSD.
-
Focused ultrasound to help veterans with PTSD
This study tests a non-invasive brain treatment using low intensity focused ultrasound to see if it can reduce PTSD symptoms and improve daily functioning in veterans.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.